Human Genome Sciences Plans to Move LymphoStat-B To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.